Quantcast

Accenture and Bayer streamline drug development processes through Intient clinical platform

Accenture (NYSE: ACN) has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes. The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing platform, creating actionable insights to accelerate drug development and improve patient outcomes.

Read more

Bayer names head of Business Development & Licensing Pharmaceutical business in USA

Bayer named Marianne De Backer PhD as the new Head of Business Development & Licensing of its Pharmaceuticals Division. She will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company’s Pharmaceuticals Division and join the Pharmaceuticals Executive Committee with immediate effect.

Read more

Three companies to evaluate the combination of Bayer’s kinase inhibitor Stivarga and BMS’s Opdivo

Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1

Read more